38.13
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene fam…
Eukaryotic cells employ numerous intracellular and extracellular signaling cascades to respond appropriately to the external stimuli as well as to maintain their normal physiological functions.
These signaling cascades are controlled by a diverse set of intracellular regulatory proteins, such as the Ras proteins.
Ras is a family of GTPases involved in the regulation of signaling pathways that control cell growth and proliferation.
These proteins are anchored to the cytoplasmic side of the plasma membrane, and transit between two states - the GTP bound active state, and the GDP bound inactive state.
In a healthy cell, an appropriate signaling molecule activates the tyrosine kinase receptor present on the cell surface.
The active receptor helps to recruit adapter proteins and Ras guanine nucleotide exchange factors or Ras GEFs, which act as a link between the receptor and the Ras protein.
The Ras GEFs then replace the GDP bound to the inactive RAS protein with a GTP, switching it into an active state.
The active Ras protein then further transmits the signal via a signaling cascade to activate the mitogen-activated protein kinase or MAP kinase.
The active MAP kinase phosphorylates transcription factors that turn on the genes encoding growth-promoting proteins and facilitate controlled cell growth and division.
However, Ras is a proto-oncogene that, upon hyperactivation can lead to uncontrolled proliferation of cells.
In normal situations, the cell employs special proteins called Ras GTPase-activating proteins or GAPs that can hydrolyze the GTP bound to the active Ras and transform it back to the inactive state.
But in the case of a Ras mutation, the altered protein may not allow Ras GAPs to hydrolyze the GTP.
This effectively turns RAS into a hyperactive protein which is constitutively active, even in the absence of external stimuli, and continuously transmits growth signals to the downstream signaling molecules. The result is uncontrolled cell growth and proliferation.
Mutations in the Ras genes have implications in many human cancers, especially colorectal cancer.
View the full transcript and gain access to JoVE Core videos
Q1: What is the Ras gene and why is it important in cancer research?
The Ras gene is a proto-oncogene that encodes a protein involved in cell signaling and growth regulation. When mutated, Ras becomes hyperactive, driving uncontrolled cell division and contributing to cancer development. Understanding Ras mutations is central to cancer research because they occur frequently in human tumors and represent a key target for therapeutic intervention.
Q2: How do Ras mutations lead to cancer development?
Ras mutations alter the protein's structure, causing it to remain in an active state and continuously signal for cell growth. This persistent activation bypasses normal cellular checkpoints that prevent uncontrolled division. The mutated Ras protein drives excessive proliferation, allowing cells to accumulate additional mutations and progress toward malignancy.
Q3: What are the different types of Ras gene mutations found in cancer?
Ras mutations typically occur at specific codons, most commonly at positions 12, 13, and 61. These point mutations result in amino acid substitutions that impair the protein's ability to hydrolyze GTP, locking Ras in its active form. Different mutation types are associated with distinct cancer types, reflecting tissue-specific vulnerabilities.
Q4: How does normal Ras protein function in healthy cells?
Normal Ras protein acts as a molecular switch in cell signaling pathways, cycling between inactive GDP-bound and active GTP-bound states. When growth signals activate Ras, it recruits downstream effectors to promote controlled cell growth and division. GTPase activity then hydrolyzes GTP to GDP, returning Ras to its inactive state and terminating the signal.
Q5: What percentage of human cancers involve Ras gene mutations?
Ras mutations are among the most common oncogenic alterations in human cancer, occurring in approximately 30% of all tumors. Specific cancer types show higher frequencies, with pancreatic cancer exceeding 90% and colorectal cancer around 50%. This prevalence makes Ras a critical focus for understanding cancer biology and developing targeted therapies.
Q6: Why is targeting Ras mutations challenging for cancer treatment?
Ras proteins lack obvious binding pockets for small-molecule inhibitors, making direct drug targeting difficult. The protein's high affinity for GTP and rapid nucleotide exchange complicate therapeutic approaches. Recent advances in allele-specific inhibitors and combination strategies are beginning to overcome these challenges, offering new hope for Ras-driven cancers.